PVT1 and neoplasm: Strikingly short-term knockdown of Pvt1 (within 96 h of shRNA administration) was sufficient to cause a significant reduction in tumor burden, suggesting that transient dynamic changes occurring during disease progression may be adequate at impacting disease outcomes.